PF-Atlas › Clinical Trials › NCT00222521

Insulin Glargine Vs Standard Insulin Therapy

Glargine insulin · Phase 3

Registry ID
NCT00222521
Phase
Phase 3
Status
Completed
Drug / intervention
Glargine insulin
Sponsor
University of Minnesota
Start
2003-04
Enrollment
20
Locations
1

About this trial

This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.

View NCT00222521 on ClinicalTrials.gov →

Explore related

All Glargine insulin trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00222521 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.